178 related articles for article (PubMed ID: 38596681)
41. Chemokines as Drivers of the Autoimmune Destruction in Type 1 Diabetes: Opportunity for Therapeutic Intervention in Consideration of an Optimal Treatment Schedule.
Christen U; Kimmel R
Front Endocrinol (Lausanne); 2020; 11():591083. PubMed ID: 33193102
[TBL] [Abstract][Full Text] [Related]
42. Regulatory T Cells Induced by Single-Peptide Liposome Immunotherapy Suppress Islet-Specific T Cell Responses to Multiple Antigens and Protect from Autoimmune Diabetes.
Bergot AS; Buckle I; Cikaluru S; Naranjo JL; Wright CM; Zheng G; Talekar M; Hamilton-Williams EE; Thomas R
J Immunol; 2020 Apr; 204(7):1787-1797. PubMed ID: 32111734
[TBL] [Abstract][Full Text] [Related]
43. Peripheral and islet interleukin-17 pathway activation characterizes human autoimmune diabetes and promotes cytokine-mediated β-cell death.
Arif S; Moore F; Marks K; Bouckenooghe T; Dayan CM; Planas R; Vives-Pi M; Powrie J; Tree T; Marchetti P; Huang GC; Gurzov EN; Pujol-Borrell R; Eizirik DL; Peakman M
Diabetes; 2011 Aug; 60(8):2112-9. PubMed ID: 21659501
[TBL] [Abstract][Full Text] [Related]
44. Effect of the PTPN22 and INS risk genotypes on the progression to clinical type 1 diabetes after the initiation of β-cell autoimmunity.
Lempainen J; Hermann R; Veijola R; Simell O; Knip M; Ilonen J
Diabetes; 2012 Apr; 61(4):963-6. PubMed ID: 22357962
[TBL] [Abstract][Full Text] [Related]
45. Pancreas in recent onset insulin-dependent diabetes mellitus. Changes in HLA, adhesion molecules and autoantigens, restricted T cell receptor V beta usage, and cytokine profile.
Somoza N; Vargas F; Roura-Mir C; Vives-Pi M; Fernández-Figueras MT; Ariza A; Gomis R; Bragado R; Martí M; Jaraquemada D; Pujol-Borrell R
J Immunol; 1994 Aug; 153(3):1360-77. PubMed ID: 7913115
[TBL] [Abstract][Full Text] [Related]
46. Emerging Therapeutic Strategies to Restore Regulatory T Cell Control of Islet Autoimmunity in Type 1 Diabetes.
Volfson-Sedletsky V; Jones A; Hernandez-Escalante J; Dooms H
Front Immunol; 2021; 12():635767. PubMed ID: 33815387
[TBL] [Abstract][Full Text] [Related]
47. Tolerogenic Immune-Modifying Nanoparticles Encapsulating Multiple Recombinant Pancreatic β Cell Proteins Prevent Onset and Progression of Type 1 Diabetes in Nonobese Diabetic Mice.
Podojil JR; Genardi S; Chiang MY; Kakade S; Neef T; Murthy T; Boyne MT; Elhofy A; Miller SD
J Immunol; 2022 Aug; 209(3):465-475. PubMed ID: 35725270
[TBL] [Abstract][Full Text] [Related]
48. T-cell mediated autoimmunity to the insulinoma-associated protein 2 islet tyrosine phosphatase in type 1 diabetes mellitus.
Dotta F; Dionisi S; Viglietta V; Tiberti C; Matteoli MC; Cervoni M; Bizzarri C; Marietti G; Testi M; Multari G; Lucentini L; Di Mario U
Eur J Endocrinol; 1999 Sep; 141(3):272-8. PubMed ID: 10474125
[TBL] [Abstract][Full Text] [Related]
49. Cellular islet autoimmunity associates with clinical outcome of islet cell transplantation.
Huurman VA; Hilbrands R; Pinkse GG; Gillard P; Duinkerken G; van de Linde P; van der Meer-Prins PM; Versteeg-van der Voort Maarschalk MF; Verbeeck K; Alizadeh BZ; Mathieu C; Gorus FK; Roelen DL; Claas FH; Keymeulen B; Pipeleers DG; Roep BO
PLoS One; 2008 Jun; 3(6):e2435. PubMed ID: 18560516
[TBL] [Abstract][Full Text] [Related]
50. miRNA92a targets KLF2 and the phosphatase PTEN signaling to promote human T follicular helper precursors in T1D islet autoimmunity.
Serr I; Fürst RW; Ott VB; Scherm MG; Nikolaev A; Gökmen F; Kälin S; Zillmer S; Bunk M; Weigmann B; Kunschke N; Loretz B; Lehr CM; Kirchner B; Haase B; Pfaffl M; Waisman A; Willis RA; Ziegler AG; Daniel C
Proc Natl Acad Sci U S A; 2016 Oct; 113(43):E6659-E6668. PubMed ID: 27791035
[TBL] [Abstract][Full Text] [Related]
51. Thymic self-antigens for the design of a negative/tolerogenic self-vaccination against type 1 diabetes.
Geenen V; Mottet M; Dardenne O; Kermani H; Martens H; Francois JM; Galleni M; Hober D; Rahmouni S; Moutschen M
Curr Opin Pharmacol; 2010 Aug; 10(4):461-72. PubMed ID: 20434402
[TBL] [Abstract][Full Text] [Related]
52. Electrospray ionization mass spectrometric analyses of phospholipids from INS-1 insulinoma cells: comparison to pancreatic islets and effects of fatty acid supplementation on phospholipid composition and insulin secretion.
Ramanadham S; Hsu F; Zhang S; Bohrer A; Ma Z; Turk J
Biochim Biophys Acta; 2000 Apr; 1484(2-3):251-66. PubMed ID: 10760474
[TBL] [Abstract][Full Text] [Related]
53. Characterization of anti-islet cytotoxic human T-cell clones from patients with type 1 diabetes mellitus.
Sobel DO; Creswell K
Autoimmunity; 2006 Jun; 39(4):323-32. PubMed ID: 16891221
[TBL] [Abstract][Full Text] [Related]
54. Identifying New Hybrid Insulin Peptides (HIPs) in Type 1 Diabetes.
Mannering SI; Rubin AF; Wang R; Bhattacharjee P
Front Immunol; 2021; 12():667870. PubMed ID: 33995402
[TBL] [Abstract][Full Text] [Related]
55. Disease-modifying immunotherapy for the management of autoimmune diabetes.
Castro CN; Barcala Tabarrozi AE; Noguerol MA; Liberman AC; Dewey RA; Arzt E; Morelli AE; Perone MJ
Neuroimmunomodulation; 2010; 17(3):173-6. PubMed ID: 20134195
[TBL] [Abstract][Full Text] [Related]
56. Modulation of Autoimmune T-Cell Memory by Stem Cell Educator Therapy: Phase 1/2 Clinical Trial.
Delgado E; Perez-Basterrechea M; Suarez-Alvarez B; Zhou H; Revuelta EM; Garcia-Gala JM; Perez S; Alvarez-Viejo M; Menendez E; Lopez-Larrea C; Tang R; Zhu Z; Hu W; Moss T; Guindi E; Otero J; Zhao Y
EBioMedicine; 2015 Dec; 2(12):2024-36. PubMed ID: 26844283
[TBL] [Abstract][Full Text] [Related]
57. Doubly Reactive INS-IGF2 Autoantibodies in Children with Newly Diagnosed Autoimmune (type 1) Diabetes.
Kanatsuna N; Delli A; Andersson C; Nilsson AL; Vaziri-Sani F; Larsson K; Carlsson A; Cedervall E; Jönsson B; Neiderud J; Elding Larsson H; Ivarsson SA; Törn C; Fex M; Lernmark Å
Scand J Immunol; 2015 Oct; 82(4):361-9. PubMed ID: 26073034
[TBL] [Abstract][Full Text] [Related]
58. Antibodies to post-translationally modified insulin as a novel biomarker for prediction of type 1 diabetes in children.
Strollo R; Vinci C; Napoli N; Pozzilli P; Ludvigsson J; Nissim A
Diabetologia; 2017 Aug; 60(8):1467-1474. PubMed ID: 28526919
[TBL] [Abstract][Full Text] [Related]
59. Deciphering the Pathogenesis of Human Type 1 Diabetes (T1D) by Interrogating T Cells from the "Scene of the Crime".
Kent SC; Mannering SI; Michels AW; Babon JAB
Curr Diab Rep; 2017 Sep; 17(10):95. PubMed ID: 28864875
[TBL] [Abstract][Full Text] [Related]
60. Prevention of "Humanized" diabetogenic CD8 T-cell responses in HLA-transgenic NOD mice by a multipeptide coupled-cell approach.
Niens M; Grier AE; Marron M; Kay TW; Greiner DL; Serreze DV
Diabetes; 2011 Apr; 60(4):1229-36. PubMed ID: 21346176
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
